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Abstract
Purpose Platelets are essential for primary hemostasis; howev-
er, platelet activation also plays an important proinflammatory
role. Inflammation promotes the development of cardiac fi-
brosis and heart failure induced by hypertension. In this study,
we aimed to determine whether inhibiting platelet activation
using clopidogrel could inhibit hypertension-induced cardiac
inflammation and fibrosis.
Methods Using a mouse model of angiotensin II (Ang II)
infusion (1,500 ng/[kg·min] for 7 days), we determined the role
of platelet activation in Ang II infusion-induced cardiac inflam-
mation and fibrosis using a P2Y12 receptor inhibitor, clopidogrel
(50 mg/[kg·day]).
Results CD41 staining showed that platelets accumulated in
Ang II-infused hearts. Clopidogrel treatment inhibited Ang II
infusion-induced accumulation of α-SMA+ myofibroblasts and
cardiac fibrosis (4.17±1.26 vs. 1.46±0.81, p<0.05). Infiltration of
inflammatory cells, includingMac-2+ macrophages and CD45+L
y6G+ neutrophils (30.38±4.12 vs. 18.7±2.38, p<0.05), into Ang
II-infused hearts was also suppressed by platelet inhibition. Real-
timePCRand immunohistochemical staining showed that platelet
inhibition significantly decreased the expression of interleukin-1β
and transforming growth factor-β. Acute injection of Ang II or
PE stimulated platelet activation and platelet-leukocyte conjuga-
tion, which were abolished by clopidogrel treatment.
Conclusion Thus, inhibition of platelet activation by clopido
grel prevents cardiac inflammation and fibrosis in response to
Ang II. Taken together, our results indicate Ang II infusion-
induced hypertension stimulated platelet activation and
platelet-leukocyte conjugation, which initiated inflammatory
responses that contributed to cardiac fibrosis.
Keywords Clopidogrel . Platelet activation . Inflammation .
Hypertension . Cardiac fibrosis
Introduction
Cardiac fibrosis is an important pathological feature of cardiac
remodeling in hypertension [1]. Increased fibrosis and subse-
quent cardiac dysfunction can cause heart failure, arrhythmia,
and even sudden death [2]. Among the numerous risk factors
for cardiac fibrosis, the renin-angiotensin-aldosterone system
(RAAS), particularly the key effector molecule angiotensin II
(Ang II), is of primary importance. Elevated Ang II levels are a
well-established risk factor for the development of hypertension,
and Ang II is also an important proinflammatory and profibrotic
factor in cardiac remodeling [3–5]. Increasing evidence has
indicated that inflammation plays a key role in the process of
cardiac remodeling [6]. Multiple inflammatory cells and cyto-
kines were reported to be involved in the process of cardiac
fibrosis. Elevated blood pressure is important for initiating in-
flammatory responses; hydralazine, a direct-acting smooth mus-
cle relaxant, decreased collagen expression and production of
several profibrotic cytokines in a rat model of DOCA-salt
induced inflammation and fibrosis or Ang II infusion-induced
cardiac fibrosis through lowering of the elevated blood pressure
[7, 8]. However, the early events that initiate inflammation in
response to hypertension remain unknown.
Platelets are unnucleated fragments of bone marrow mega-
karyocytes. In addition to hemostasis and thrombosis, platelets
are involved in inflammatory and immune processes. As a
“monitor” of blood flow, platelets are sensitive to any circulation
anomaly. Endothelial cell damage or sheer stress conditions [9,
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10] activate platelets and stimulate the expression of specific
adhesion molecules (e.g., P-selectin, CD40, CD154, and GP
IIb/IIIa) and secretion of cytokines and chemokines [11, 12].
Activated platelets interact with neutrophils, monocytes/macro
phages, and T cells via surface molecule binding to specific
ligands or receptors, such as P-selectin/P-selectin glycoprotein
ligand-1 (PSGL-1), CD40/CD154, and Mac-1/αIIbβ3 [13, 14].
Platelet activation is involved in the process of atherosclerosis,
myocardial infarction, and other cardiovascular diseases [13].
We hypothesized that Ang II-induced hypertension might acti-
vate platelets, which initiate inflammation and contribute to
cardiac fibrosis development.
In the present study, we used clopidogrel, a P2Y12 subtype
ADP receptor inhibitor, to block platelet activation [15]. We
found that platelet activation was an early event in response to




Ang II and phenylephrine (PE) were purchased from sigma
chemicals (Sigma,St Louis, Missouri, USA). Clopidogrel
(Plavix, Sanofi-Aventis) was purchased from local pharma-
cy. A 75 mg/tablet clopidogrel was dissolved in 15 ml 0.9 %
saline, and the clopidogrel solution was freshly prepared
every day. Clopidogrel or vehicle was administered
intragastrically to mice for 7 days during the Ang II infusion
(at a concentration of 50 mg/kg, once daily) as previously
described. [16, 17]
Animal Model
Two-month old male C57/BL6 mice (22 g to 25 g) were pur-
chased from Academy of Military Sciences (Beijing, China). All
animal care and experimental protocols complied with the Ani-
mal Management Rule of the Ministry of Health, People’s Re-
public of China (Documentation no. 55, 2001) and the Guide for
the Care and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication no. 85–23, revised
1996) and were approved by the Institutional Animal Care and
Use and Committee of the Capital University of Medical
Science.
Mice were randomly divided into 4 groups (8 in each
group). The mice were anesthetized with sodium pentobar-
bital (50 mg/kg IP). Ang II was dissolved in 0.01 N acetic
acid saline solution. With a sterile technique, osmotic
minipumps (Alzet MODEL 1007D, DURECT, Cupertino,
CA, USA) with Ang II or vehicle (untreated) were placed
subcutaneously in the intrascapular area to deliver Ang II at
an infusion rate of 1,500 ng/kg per minute for 7 days. Drug
or vehicle administration was well tolerated by all animals
and no animal died or displayed signs of discomfort in any
group.
Blood Pressure Measurement
Mice were trained daily for 3 days to have systolic blood
pressure (SBP) determined with a computerized mouse tail-
cuff system (BP-98A softron, Tokyo, Japan). Ten to twenty
repeated values were averaged at each determination point.
SBP was determined before and at the 4th-7th days of the Ang
II infusion.
Cardiac Echocardiography
Mice were anesthetized with isoflurane and analyzed for
structural and function by use of the Vevo 770 high-
resolution microimaging system with a 30 MHz transduser
(Visualsonic, Toronto, Canada). The heart was imaged in the
2D mode in the parasternal short-axis view.
Echocardiographic measurements were taken on M-mode
in triplicate from all 8 mice per group as previously described
with minor modification [18, 19].
Bleeding Time Measurement
Bleeding time was measured through a tail transection method
as previously described with minor modification [20] . Briefly,
the maximum bleeding time for recording was 900 s, and the
terminal point was the end of bleeding; Moreover, bleeding
time recording continued until a new arrest lasting for more
than 30 s had occurred if the bleeding restarted within 30 s.
Preparation of Tissue Sections and Histopathology
Hearts were embedded in paraffin serial sections (5 μm) and
cut and placed on polysinecoated glass slides as described
[21–23]. To measure the size of cardiomyocytes, heart sec-
tions were deparaffinized and incubated with 100 μg/ml
FITC-labeled WGA (Sigma) for 90 min. At least 50 cells
were measured to calculate the area per slide. For morpho-
logical staining, heart sections were also stained with hema-
toxylin and eosin or Masson’s trichrome reagent. Cardiac
fibrosis was quantitated in a blinded fashion by measuring
the total blue area (mm2) with a NIS- ELEMENTS quanti-
tative automatic program (Nikon, Japan) in the Masson’s
trichrome-stained heart sections. For immunostaining,
deparaffinized heart sections (5 μm) were incubated with
avidin, biotin (Maixin, Fuzhou, China) for 15 min. After
the inactivation of endogenous peroxides, they were incu-
bated with anti-mouse monoclonal antibodies against Mac-
2(1:400 dilution), interleukin-1β (IL-1β) (1:200 dilution),
transforming growth factor-β (TGF-β) (1:300 dilution) and
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α-smooth muscle actin (α-SMA) (1:200 dilution, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) at 4 °C overnight. The
sections were then incubated with biotinylated secondary goat
anti rabbit antibody for 30 min at 37 °C. After being incubated
with diaminobenzidine tetrahydrochloride, sections were coun-
ter stained using hematoxylin, dehydrated through gradient
alcohols, and mounted with cover slips. Images were obtained
using a CCD camera under a microscope (ECLIPSE80i/90i,
Nikon, Japan) with a ×200 lens, and 10–20fields/section were
chosen randomly from 8 mice per group. For CD41 staining,
frozen heart sections were labeled with anti mouse monoclonal
antibody against CD41 (1:100 dilution, Abcam, Cambridge,
MA), then incubated with FITC-conjugated secondary anti-
body (JacksonImmunoResearch Laboratories, West Grove,
PA). Images were captured by use of a Nikon Eclipse
TE2000-S microscope (Nikon, Japan).
Flow Cytometric Analysis
The inflammatory cells infiltrated were quantified by flow
cytometry as described previously by our laboratory [18,
24]. Briefly, heart tissues were quickly minced into multiple
small tubes and digested in an enzyme mixture, which con-
tains collagenase type I (0.05 mg/ml) and type IV (0.05-
mg/ml), hyaluronidase (0.025mg/ml), DNase I (0.01mg/ml)
and soybean trypsin inhibitor (0.01 mg/ml) dissolved in
DMEM for 45 min at 37 °C. The cell suspension was
centrifuged and preincubated with Fc-γ block antibody (an-
ti-mouse CD16/32; Pharmingen, San Diego, CA) to prevent
nonspecific binding, further stained with antibodies PE-
conjugated antimouse CD45 and PerCP/Cy5.5-conjugated
antimouse Ly6G for 30 min at 4 °C in the dark. Data were
collected by use of an EPICS XL flow cytometer (Beckman
Coulter, Miami, FL) and analyzed by use of Cellquest
(Beckman). Total cell population was recorded by cell size
(forward scatter) and internal complexity (side scatter) and
showed even distribution in a representative cell suspension
prepared from heart tissues. Leukocytes were stained with
monoclonal anti-CD45 and gated with CD45 fluorescence
versus side scatter, while Ly6G+ neutrophils were further
gated on CD45+ cells. Appropriate isotype controls of irrel-
evant specificity were performed.
To quantify the platelet activation and consequently
platelet-leukocyte conjugation, peripheral blood was
obtained from mice via lateral caudal vein, then underwent
erythrocyte lysis using FACS lysing solution according to
the manufacture’s instruction (BD Biosciences). Leukocytes
were labeled with PerCP/Cy5.5-conjugated anti-mouse
CD45.2 (Biolegend, San Diego, CA), while platelets were
labeled with PE-conjugated anti-mouse CD41 and FITC-
conjugated anti-mouse CD62P (both BD Bioscience) for
30 min at 4 °C in the dark. Data were collected by flow
cytometry (Beckman Coulter).
RNA Analysis
Total RNA was extracted by the Trizol reagent method
(Invitrogen, Carslbad, CA, USA), and cDNA was synthe-
sized according to the manufacturers’ instruction (Promega,
Southhampton, UK). The housekeeping gene GAPDH was
used as control. Primers used in this study were for collagen
I, forward 5′-GAGCGGAGAGTACTGGATCG-3′ and reverse
5′-TACTCGAACGGGAATCCATC-3′; IL-1β, forward 5′-
CTTCAGGCAGGCAGTATCACTCAT-3′ and reverse 5′-
TCTAATGGGAACGTCACACACCAG-3′; TGF-β, forward
5′-CAACAATTCCTGGCGTTACCTTGG-3′ and reverse 5′-
GAAAGCCCTGTATTCCGTCTCCTT-3′ and GAPDH, for-
ward 5′-CCTGGAGAAACCTGCCAAGTATGA-3′ and re-
verse 5′-TTGAAGTCACAGGAGACAACCTGG-3′. Real-
time PCR was carried out with the use of Bio-Rad iQ5
(Hercules, CA, USA).
Acute Studies
To study the role of the platelets in Ang II-induced acute
hypertension, male mice were anesthetized with sodium pento-
barbital (50mg/kg IP). Two hours before Ang II or PE injection,
mice were treated with clopidogrel or PBS intragastrically at a
concentration of 50 mg/kg. Mice were then placed on a heating
platform for 10 min. Blood pressure was measured every 30 s
for 25 min with a mouse tail-cuff system (BP-98A softron).
After 5 min of baseline SBP recording, acute hypertension in
anesthetizedmicewas inducedwith anAng II or PE injection as
reported (0.2 mg/kg, IP)[25, 26]. About 10 min after Ang II or
PE injection, a blood sample was collected frommice via lateral
caudal vein using glass pipettes dipped in 3.8 % sodium citrate
solution (Sigma-Aldrich) for flow cytometric analysis. Bleed-
ing time was monitored after blood sample collection.
Statistical Analysis
Data are expressed as mean ± SEM. Statistical significance
of the results was calculated by Student’s t test using
Graphpad software (GraphPad Prism version 5.00 for Win-
dows; GraphPad Software Inc. San Diego, California, USA);
A p<0.05 was considered statistically significant. The Mann
Whitney test was applied to the studies of bleeding time.
Results
Clopidogrel Treatment Prolonged the Bleeding Time, but it
did not Affect Blood Pressure and Cardiac Function in Ang
II-infused Mice
To determine the role of platelets in Ang II infusion-induced
cardiac fibrosis, clopidogrel was used to inhibit platelet activation
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[27]. As shown in Fig. 1a, there was an increase in systolic blood
pressure after Ang II infusion in both the vehicle- and
clopidogrel-treated groups. As expected, clopidogrel treatment
significantly prolonged tail bleeding time (Fig. 1b). WGA stain-
ing showed that Ang II infusion increased cardiomyocyte size,
which was partly suppressed by clopidogrel treatment (Fig. 1c).
Echocardiography revealed that clopidogrel treatment reduced
Ang II infusion-induced increased LV mass (Fig. 1d), while the
cardiac ejection fraction, LV wall thickness, diameter, and frac-
tional shortening were similar between the groups (data not
shown).
Clopidogrel Treatment Inhibited Ang II Infusion-Induced
Platelet Deposition and Cardiac Fibrosis
To examine the effect of platelet activation on Ang II infusion-
induced cardiac fibrosis, we performed CD41 immunofluores-
cence staining after 7 days in mice hearts. Ang II infusion
stimulated CD41+ platelet deposition in the heart, which was
inhibited by clopidogrel treatment (Fig. 2a). As shown in Fig. 2b
and c, Ang II infusion significantly increased perivascular and
interstitial fibrosis (4.17±1.26 vs. 1.46±0.81, p<0.05), as well
as α-SMA+ myofibroblast accumulation, which were de-
creased with clopidogrel treatment. Furthermore, Ang II infu-
sion increased collagen I mRNA expression, which was also
suppressed by clopidogrel treatment (Fig. 2d).
Inhibition of Platelet Activation Prevented Ang II Infusion-
Induced Inflammatory Cell Infiltration in the Heart
It has been reported that inflammatory cell infiltration into the
heart is responsible for cardiac fibrosis [28], and platelets
interact with several types of inflammatory cells that are
critical for initiation of inflammation [12]. We therefore ex-
amined the effect of platelet activation on inflammatory cell
infiltration. As shown in Fig. 3a, a large number of inflamma-
tory cells infiltrated the hearts of Ang II-infused mice, which























bleeding time p value
vehicle 151± 27.93s
vehicle+clopidogrel 900s **
Ang II 232± 47.64s **
Ang II+clopidogrel 900s **##
**p<0.01 vs. vehicle   















































































Fig. 1 Clopidogrel treatment
does not affect the blood
pressure and cardiac function
after Ang II infusion. a Blood
pressure measurement in
clopidogrel or vehicle treated
groups before and on the 4th
day and 6th day of Ang II
infusion (n=8). b The tail
transection method was used to
measure the bleeding time on
the 7th day of Ang II or vehicle
infusion with clopidogrel or
vehicle treatment; cWheat germ
agglutinin staining was used to
evaluate cardiomyocyte size in
heart sections of Ang II or
vehicle infused heart with
clopidogrel or vehicle treatment
(top, Bar=50 μm); Quantitative
analysis of cardiomyocyte
cross-sectional area (bottom); d
Echocardiography was
performed at day 7 after Ang II
infusion. *p<0.05,**p<0.01
vs. vehicle group, #p<0.05,
##p<0.01 vs. Ang II group. Ang
II: angiotensin II
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macrophages was also decreased by clopidogrel treatment in
Ang II-infused mouse hearts (Fig. 3a). To further quantitate the
inflammatory cell infiltrates in Ang II-infused hearts, flow
cytometric analysis was used to measure CD45+ inflammatory
cells and CD45+ Ly6G+ neutrophils. As shown in Fig. 3b and c,
Ang II infusion increased CD45+ cell infiltration compared to
the vehicle-treated group, with CD45 and Ly6G double-positive
neutrophils comprising a large proportion (30.38±4.12 vs.
18.7±2.38, p<0.05), whereas clopidogrel treatment significant-
ly suppressed both CD45+ and CD45+Ly6G+ cell infiltration.
Inhibition of Platelet Activation Suppressed Ang II Infusion-
Induced Cytokine Expression
TGF-β is a well-established profibrotic cytokine, and IL-1β is an
important cytokine that is involved in cardiac fibrosis [29, 30].
As both of these cytokines are secreted by activated platelets, we
examined their expression in the mouse hearts. Immunohisto-
chemical staining showed that clopidogrel treatment inhibited
both TGF-β (8.09±3.21 vs. 2.34±0.59, p<0.01) and IL-1β
expression (7.14±1.91 vs. 0.99±0.27, p<0.01), which were
significantly upregulated in Ang II-infused mouse hearts (Fig. 4a
and b). Moreover, real-time PCR analysis showed that Ang II
increased mRNA expression of these two cytokines, which was
also suppressed by clopidogrel treatment (Fig. 4c).
Platelet Activation is an Early Event in Ang II Injection-
Induced Hypertension
We previously reported that Ang II infusion-induced cardiac
inflammation and fibrosis is pressure dependent [8]. There-
fore, we tested whether platelet activation is the early event
associated with this elevation in blood pressure. Acute hy-
pertension was induced via intraperitoneal injection of Ang
II. As expected, Ang II caused a rapid increase in blood
pressure (Fig. 5a). Ang II injection stimulated platelet-
leukocyte conjugation (shown as CD45+CD41+) in periph-
eral blood, which was abolished by clopidogrel treatment
(Fig. 5b and c). Furthermore, Ang II stimulated CD62P (P-
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Fig. 2 Clopidogrel treatment inhibits platelet deposition and cardiac
fibrosis in Ang II infused mice hearts a Immunofluorescence staining
for CD41 showed platelet deposition in Ang II or vehicle infused heart
(Bar=50 μm); b Representative photomicrographs from histological
sections of hearts stained with Masson’s trichrome staining (top) and
immunohistochemical staining for α-SMA (bottom) at day 7 of Ang II
or vehicle infusion in each group (Bar=50 μm). cHistogram shows less
fibrosis area and α-SMA+ area in Ang II+Clopidogrel group and d
lower mRNA level of collagen I.*p<0.05 vs. vehicle group, #p<0.05,
##p<0.05 vs. Ang II group (n=8)
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also inhibited by clopidogrel treatment. As studies have
demonstrated that Ang II can activate platelets in an AT1
dependent fashion in response to Ang II infusion [31], we
therefore used acute PE injection as reported to increase
blood pressure in an Ang II/AT1 independent fashion [25,
26]. As shown in Fig. 5a, similar to Ang II injection, PE
injection also increased blood pressure. Flow cytometric
analysis also showed that PE injection caused platelet-
leukocyte conjugation (shown as CD45+CD41+) and platelet
activation (shown as CD41+CD62P+) in the peripheral
blood, which was reduced by clopidogrel treatment (Fig. 5d).
These results demonstrated that in addition to a direct effect
of Ang II on its receptor AT1, an acute increase in blood
pressure could activate platelet-leucocyte complexes.
Discussion
We previously reported that Ang II infusion-induced cardiac
inflammation is pressure-dependent [8]; however, the early
event that occurs in response to elevated blood pressure and
triggers this inflammation remains unknown. Our present
study revealed several novel findings. (1) Ang II infusion
stimulates platelet deposition on microvessels; (2) the P2Y12
a
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Fig. 3 Clopidogrel treatment inhibits inflammatory cell infiltration in
Ang II infused mice hearts. a Representative photomicrographs from
histological sections of hearts with hematoxylin-eosin staining and
immunohistochemical staining for Mac-2 at day 7 of Ang II infusion
in each group (left panel, Bar=50 μm, n=8). Histogram shows less
Mac-2+ area in Ang II+ Clopidogrel group (right panel). b Leukocytes
are gated with CD45 fluorescence versus side-angle scatter (SS). Scatter
plots are gated on CD45+population cells (left panel); Histogram shows
decreased leukocytes infiltrated in Ang II infused heart after clopidogrel
treatment (right panel, n=4). c Infiltrated neutrophils (CD45+Ly6G+
cells) were analyzed in each group after 7 days of Ang II or vehicle
infusion. Data are mean ± SEM (n=4). *p<0.05 vs. vehicle group,
#p<0.05 vs. Ang II group
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antagonist clopidogrel used to inhibit the platelet activation
decreases Ang II infusion-induced cardiac inflammation and
fibrosis; and (3) acute elevation of blood pressure stimulates
platelet activation and platelet-leukocyte conjugation, which
was abrogated by clopidogrel treatment. Thus, inhibition of
platelet activation by clopidogrel prevents cardiac inflamma-
tion and fibrosis in response to Ang II. Our results suggest
that platelet activation in response to elevated blood pressure
may be an early event that initiates inflammation in Ang II-
infused mice.
Increasing evidence has shown that platelets function as an
immune modulator in several inflammation-associated pro-
cesses [32]. Clinical studies have reported that low-grade
inflammation and persistent platelet activation are present in
patients with hypertension, particularly those with complica-
tions (e.g. vascular lesions and microalbuminuria) [33–36].
Consistent with these studies, our study provides direct evi-
dence that platelet activation is involved in hypertension-
induced cardiac inflammation and fibrosis (Fig. 2). Our results
show that Ang II infusion induces platelet activation and
platelet-leukocyte conjugation. These results are consistent
with studies showing that Ang II injection induces platelet
activation in humans [37]. It has also been reported that Ang II
promotes platelet aggregation at lower concentrations in hu-
man platelets via the AT1 receptor, which can be inhibited by
AT1 receptor antagonists [31]. Moreover, AT1 receptor antag-
onists inhibit platelet adhesion (collagen-stimulated) and ag-
gregation (U46619-stimulated) in a dose-dependent manner
[38]. Taken together with our results, we conclude that ele-
vated blood pressure and the Ang II receptor stimulate platelet
activation, platelet-leukocyte conjugation, and cardiac inflam-
mation in response to Ang II infusion.
Activated platelets have been shown to stimulate platelet-
leukocyte interactions, which are involved in the pathogen-
esis of several inflammatory diseases [39]. Liu et al. found
that myocardial infarction evokes platelet accumulation and
platelet-leukocyte conjugation in infarcted hearts in as early
as 6 h, which is responsible for local and systemic inflam-
mation, leading to cardiac remodeling and cardiac rupture in
a P-selectin/PSGL-1-dependent manner [40]. Importantly,
antiplatelet interventions including clopidogrel or anti-
CD41 antibody-mediated platelet deletion suppressed these
inflammatory responses. In a murine model of cutaneous
arthus reaction in which immune complex challenge-
induced neutrophil and mast cell accumulation is necessary
for edema and hemorrhage, platelets were found to regulate



































































































Fig. 4 Clopidogrel treatment decreases inflammatory cytokine production
in Ang II infused mice hearts. a Immunohistochemical analysis of cytokine
expression was detected by anti-IL-1β and anti-TGF-β in Ang II or vehicle
infused heart sections with clopidogrel or vehicle treatment (Bar=50 μm,
n=8). b Histogram shows less IL-1β+ and TGF-β+ area in clopidogrel
treated group and c a lower mRNA level of IL-1β and TGF-β. Data are
mean ± SEM for n=8mice with 10 fields per animal. **p<0.01 vs. vehicle
group, ##p<0.01 vs. Ang II group. IL-1β: interleukin-1β, TGF-β:
transforming growth factor-β
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leukocyte recruitment through the interaction of P-
selectin/PSGL-1 [41]. Several studies have demonstrated
that circulating activated platelets and platelet-leukocyte
conjugation are causal factors of inflammation in rescue
experiments with P-selectin-deficient or wild-type platelets.
Huo et al. [42] reported that activated platelet-monocyte
complex formation promotes leukocyte binding to VCAM-
1 and increases their adhesiveness to inflamed or atheroscle-
rotic endothelium. Importantly, injection of activated wild-
type platelets, but not P-selectin-deficient platelets, increased
monocyte arrest on the surface of atherosclerotic lesions in
Apo E−/−mice. Furthermore, Pitchford et al. [43] found that
platelet-leukocyte aggregates form in the circulating blood of
patients with asthma after allergen exposure. They demon-
strated that platelets are necessary for lung leukocyte
recruitment in a murine model of asthma; pulmonary leuko-
cyte recruitment in platelet-depleted mice transfused with
unstimulated platelets was abolished, while transfusion with
activated platelets from wild-type but not from P-selectin-
deficient mice, or wild-type platelets in the presence of an
anti-P-selectin antibody, were able to restore pulmonary
leukocyte recruitment. In addition, using antibody targeting
of integrin Mac-1 reduced platelet-dependent leukocyte ad-
hesion and recruitment following vascular injury [44]. Along
with these studies, our finding that Ang II-infusion induced
platelet-leukocyte conjugation could be a causal event for
initiation of cardiac inflammation.
In this study, platelet-leukocyte conjugation was also in-
volved in Ang II infusion-induced cardiac fibrosis, whereas



























































































































































Fig. 5 Clopidogrel treatment suppresses Ang II injection induced platelet
activation and platelet-leukocyte conjugation. a Continuous blood pressure
measurement shows a rapid blood pressure increase in response to Ang II or
PE injection. b Clopidogrel was administrated 2 h before Ang II injection to
test its effect on platelet activation in response to elevated blood pressure.
Leukocytes were gated with CD45 fluorescence versus side-angle scatter
(SS). Platelet-leukocyte conjugation (CD45+CD41+, CD45+CD62P+) and
platelet activation (CD41+CD62P+) were analyzed in the blood samples after
c Ang II injection d PE injection with clopidogrel or vehicle treatment. Data
are mean ± SEM for n=4. #p<0.05, ##p<0.01 vs. Ang II group; †p<0.05 vs.
PE group. PE: phenylephrine
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inhibited the inflammatory response and fibrosis in the heart
(Figs. 2 and 3). Activated platelets aggregate with circulating
leukocytes and adhere to the subendothelial matrix and intact
endothelium to mediate and recruit leukocytes into the vascu-
lar wall [11, 45, 46]. In our study, inhibition of platelet
activation using clopidogrel decreased the circulating
platelet-leukocyte conjugates, reducing inflammatory cell in-
filtration into the heart (Figs. 3 and 5). Formation of platelet-
leukocyte conjugates may be physiologically important, as
this process not only mediates leukocyte infiltration but also
releases a set of potent inflammatory substances during the
adhesion process, including growth factors (e.g. TGF-β,
platelet-derived growth factor, and fibroblast growth factor),
cytokine-like factors (e.g. IL-1β, CD40 ligand, and β-
thromboglobulin), and chemokines (e.g. RANTES, platelet
factor 4 [CXC chemokine ligand 4] [11]. TGF-β, the primary
activator of myofibroblasts, is a central mediator of fibrosis in
various conditions [3, 47, 48]. Platelets contain the largest
amount of TGF-β in the body [49]; indeed, our results showed
that inhibiting platelet activation decreased both mRNA and
protein levels of TGF-β in Ang II-infused hearts (Fig. 4). IL-1
plays a central role in the regulation of inflammatory and
fibrotic responses by inducing synthesis of proinflammatory
mediators, promoting leukocyte infiltration and activation,
andmodulating fibroblast function [30]. Bujak et al. examined
the effects of disrupted IL-1β signaling on myocardial
ischemia/reperfusion-induced cardiac remodeling using IL-1
receptor knockout mice, and noted that the absence of IL-1
signaling suppressed inflammation, followed by an attenuated
fibrotic response [30]. In the present study, we found that Ang
II infusion-induced IL-1β expression was suppressed by
clopidogrel treatment (Fig. 4), suggesting that platelet activa-
tion might be responsible for the release of this cytokine.
The present study also showed that platelet activation is an
early event in Ang II infusion-induced cardiac inflammation
and fibrosis. Ang II injection immediately stimulated blood
pressure elevation, which reached peak levels in 5 min. Under
this condition we observed that Ang II injection stimulated
platelet activation (CD41+CD62P+) and platelet-leukocyte
conjugation (CD45+CD41+, CD45+CD62P+) within 10 min
(Fig. 5). Along with our previous study showing that Ang II
infusion-induced cardiac inflammation and fibrosis is pressure
dependent [8], our present study indicates that platelet activa-
tion is an early event that initiates cardiac inflammation and
fibrosis in response to Ang II stimulation.
In summary, our study demonstrates that platelet activa-
tion is an early event in response to Ang II infusion-induced
hypertension that stimulates platelet-leukocyte conjugation
and recruits inflammatory cells into the heart, which secrete
inflammatory cytokines (IL-1β and TGF-β) and lead to
cardiac fibrosis. Inhibition of platelet activation by
clopidogrel prevents cardiac inflammation and fibrosis in
response to Angiotensin II -induced hypertension.
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